Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy

Phase 2 Completed 44 enrolled University Hospital Birmingham British Heart Foundation · collab University College London Hospitals · collab University of Oxford · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

Hypertrophic Cardiomyopathy (HCM) is a relatively common inherited heart muscle disease. Many patients experience symptoms of breathlessness, fatigue and chest pain. These symptoms are not always controlled with current therapies. Recently the investigators showed that a drug called Perhexiline markedly improved exercise capacity and symptoms in patients with heart failure. In this proposal the investigators wish to test whether Perhexiline improves exercise capacity and relieves symptoms in patients with HCM

Timeline

Start: 2006-12
Primary completion: 2010-08
Completion: 2010-08

Outcome

Met primary endpoint

paper These changes were accompanied by an improvement in primary end point (peak Vo(2)) PMID 20921440 ↗

Publications

Abozguia K, Elliott P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I, Maher AR, Kaur K, Taylor J, Henning A, Ashrafian H, Watkins H, Frenneaux M. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010 Oct 19;122(16):1562-9. doi: 10.1161/CIRCULATIONAHA.109.934059. Epub 2010 Oct 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Perhexiline	Small molecule	100 mg	—